96.5% Adverse Events reported in mCRPC patients with Tecentriq + Xtandi Combination therapy
Researchers speculated that enzalutamide (Xtandi) could be a candidate for combination with anti-PD-1 or anti-PD-L1 agents such as Tecentriq (atezolizumab) as it “can improve IFNɣ signaling and sensitize cancer cells immune-mediated cell killing “. In […]